What Researchers Did
Researchers described a case of bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla of a 54-year-old woman.
What They Found
A 54-year-old woman, who received intravenous bisphosphonates for 2 years for breast cancer bone metastases, developed ONJ around maxillary implants. After surgical resection of the sequestrum and implants, and hyperbaric oxygen therapy, her wound healed completely with no ONJ recurrence during a 6-month follow-up, though she later died from metastatic disease.
What This Means for Canadian Patients
Canadian patients receiving bisphosphonate therapy, especially intravenously, should be aware of the potential risk of osteonecrosis of the jaw, particularly around dental implants. Close monitoring and prompt management of oral symptoms are crucial, although effective treatments for bisphosphonate-related ONJ remain challenging.
Canadian Relevance
This study has no direct Canadian connection as it is a single case report from Japan.
Study Limitations
The primary limitation of this study is its design as a single case report, which prevents generalization of the findings to a broader patient population.